Of interest, the combination of the NLRP3 inhibitor with anti-CTLA-4/anti-PD-1 did not demonstrate a significant synergistic effect in regard to tumor growth but only in the frequencies of MDSC subsets. The gene discussed is CTLA4; the disease is neoplasm.